BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Regorafenib (Stivarga, BAY73-4506)

First Posted Date: 2013-05-14

Last Posted Date: 2017-02-20

Lead Sponsor: Bayer

Target Recruit Count: 24

Registration Number: NCT01853046

Regorafenib Post-marketing Surveillance

Completed

Conditions: Colorectal Neoplasms

Interventions: Drug: Regorafenib (Stivarga, BAY73-4506)

First Posted Date: 2013-04-30

Last Posted Date: 2018-08-02

Lead Sponsor: Bayer

Target Recruit Count: 1301

Registration Number: NCT01843400

Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in China

Completed

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: Sorafenib (Nexavar, BAY43-9006)

First Posted Date: 2013-04-25

Last Posted Date: 2017-12-20

Lead Sponsor: Bayer

Target Recruit Count: 302

Registration Number: NCT01839630

Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter

Phase 3

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939)

First Posted Date: 2013-04-24

Last Posted Date: 2016-07-25

Lead Sponsor: Bayer

Target Recruit Count: 60

Registration Number: NCT01839357

Descriptive, Prospective, Non-interventional Study (NIS) to Describe Mirena and Amenorrhea Related Acceptability in Contraception Indication in Medical Practice

Completed

Conditions: Female Contraception

Interventions: Drug: Levonorgestrel IUD (Mirena, BAY86-5028)

First Posted Date: 2013-04-17

Last Posted Date: 2015-09-14

Lead Sponsor: Bayer

Target Recruit Count: 35

Registration Number: NCT01833793

Phase 3 Study of Dienogest for the Treatment of Endometriosis in Chinese Patients

Phase 3

Completed

Conditions: Endometriosis

Interventions: Drug: Dienogest (Visanne, BAY86-5258)
Drug: Placebo

First Posted Date: 2013-04-02

Last Posted Date: 2015-11-25

Lead Sponsor: Bayer

Target Recruit Count: 250

Registration Number: NCT01822080

Safety and Efficacy of Oral BAY85-8501 in Patients With Non-CF (Cystic Fibrosis) Bronchiectasis

Phase 2

Completed

Conditions: Bronchiectasis

Interventions: Drug: BAY85-8501
Drug: Placebo

First Posted Date: 2013-03-26

Last Posted Date: 2015-07-09

Lead Sponsor: Bayer

Target Recruit Count: 94

Registration Number: NCT01818544

Comparison of Efficacy, Safety and Costs of Recombinant FVIII Products Between On-demand and Secondary Prophylaxis Groups in Haemophilia A Patients

Completed

Conditions: Hemophilia

Interventions: Other: Recombinant Factor VIII (Kogenate, BAY14-2222)

First Posted Date: 2013-03-26

Last Posted Date: 2020-05-27

Lead Sponsor: Bayer

Target Recruit Count: 73

Registration Number: NCT01817868

Study in Healthy Tubal Ligated Women to Evaluate Pharmacodynamics, Safety and Pharmacokinetics of BAY1002670

Phase 1

Completed

Conditions: Leiomyoma

Interventions: Drug: BAY1002670
Drug: Placebo

First Posted Date: 2013-03-22

Last Posted Date: 2014-04-21

Lead Sponsor: Bayer

Target Recruit Count: 73

Registration Number: NCT01816815

Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis

Phase 3

Completed

Conditions: Prostatic Neoplasms

Interventions: Drug: Radium-223 dichloride (Xofigo, BAY88-8223)

First Posted Date: 2013-03-14

Last Posted Date: 2018-09-19

Lead Sponsor: Bayer

Target Recruit Count: 243

Registration Number: NCT01810770

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy